HomeInsightsStock Comparison

Lupin Ltd vs Neuland Laboratories Ltd Stock Comparison

Lupin Ltd vs Neuland Laboratories Ltd Stock Comparison

Last Updated on: Jun 20, 2025

Key Highlights

  • The Latest Trading Price of Lupin Ltd is ₹ 1947 as of 20 Jun 11:14.
  • The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 yearsThe P/E Ratio of Neuland Laboratories Ltd changed from 22.5 on March 2020 to 27 on March 2024 . This represents a CAGR of 3.71% over 5 years.
  • The Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 yearsThe Market Cap of Neuland Laboratories Ltd changed from ₹ 363.66 crore on March 2020 to ₹ 8058 crore on March 2024 . This represents a CAGR of 85.83% over 5 years.
  • The revenue of Lupin Ltd for the Mar '25 is ₹ 5724 crore as compare to the Dec '24 revenue of ₹ 5821 crore. This represent the decline of -1.67% The revenue of Neuland Laboratories Ltd for the Mar '25 is ₹ 335.82 crore as compare to the Dec '24 revenue of ₹ 457.72 crore. This represent the decline of -26.63%.
  • The ebitda of Lupin Ltd for the Mar '25 is ₹ 1378 crore as compare to the Dec '24 ebitda of ₹ 1409 crore. This represent the decline of -2.23% The ebitda of Neuland Laboratories Ltd for the Mar '25 is ₹ 58.54 crore as compare to the Dec '24 ebitda of ₹ 146.28 crore. This represent the decline of -59.98%.
  • The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 782.38 crore over 8 quarters. This represents a CAGR of 31.37% The net profit of Neuland Laboratories Ltd changed from ₹ 61.88 crore to ₹ 27.81 crore over 8 quarters. This represents a CAGR of -32.96% .
  • The Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 yearsThe Dividend Payout of Neuland Laboratories Ltd changed from 16.25 % on March 2020 to 6.03 % on March 2024 . This represents a CAGR of -17.99% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Neuland Laboratories Ltd

  • Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
  • The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin.
  • Neuland Drugs & Pharmaceuticals Pvt.
  • Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
  • NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

Lupin Ltd News Hub

News

Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China

As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in C...

Read more

16 Jun 2025 11:07

News

Lupin gets USFDA nod for Oxcarbazepine ER tablets

Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER t...

Read more

09 Jun 2025 08:23

News

Lupin allots 78,930 equity shares under ESOP

Lupin has allotted 78,930 equity shares under Stock Option plans of the Company. According...

Read more

27 May 2025 15:33

News

Lupin grants 7,337 stock options

Lupin has granted 7,337 stock options on 27 May 2025. Please note that upon vesting, one s...

Read more

27 May 2025 18:42

News

Lupin enters into license and supply agreement with SteinCares

Lupin has entered into a license and supply agreement with SteinCares, a leading specialty...

Read more

26 May 2025 10:27

News

Lupin to develop next-gen inhalers using Honeywell's Solstice' Air propellant

Lupin announced today its plan to use Honeywell's Solstice' Air (HFO-1234ze cGMP) propella...

Read more

20 May 2025 19:07

Neuland Laboratories Ltd News Hub

News

Neuland Laboratories to hold AGM

Neuland Laboratories announced that the 41th Annual General Meeting(AGM) of the company wi...

Read more

17 May 2025 12:57

News

Neuland Labs drops after Q4 PAT slumps 59% YoY to Rs 28 cr

On quarter on quarter (QoQ) basis, the company's net profit declined 72.63% while revenue ...

Read more

16 May 2025 14:51

News

Board of Neuland Laboratories recommends Final Dividend

Neuland Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

15 May 2025 16:52

News

Neuland Laboratories to announce Quarterly Result

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

25 Apr 2025 10:43

News

Neuland Laboratories Ltd Spurts 2.02%

Neuland Laboratories Ltd gained 2.02% today to trade at Rs 13000. The BSE Healthcare index...

Read more

17 Apr 2025 09:30

News

Neuland Laboratories appoints Head - Manufacturing

Neuland Laboratories announced that Parag Deshmukh has been appointed as Head - Manufactur...

Read more

10 Mar 2025 15:29

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Neuland Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Neuland Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Lupin Ltd and Neuland Laboratories Ltd

Which company has a larger market capitalization, Lupin Ltd or Neuland Laboratories Ltd?

Market cap of Lupin Ltd is 88,256 Cr while Market cap of Neuland Laboratories Ltd is 15,696 Cr

What are the key factors driving the stock performance of Lupin Ltd and Neuland Laboratories Ltd?

The stock performance of Lupin Ltd and Neuland Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Neuland Laboratories Ltd?

As of June 20, 2025, the Lupin Ltd stock price is INR ₹1932.5. On the other hand, Neuland Laboratories Ltd stock price is INR ₹12234.4.

How do dividend payouts of Lupin Ltd and Neuland Laboratories Ltd compare?

To compare the dividend payouts of Lupin Ltd and Neuland Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions